Location：Home/News/Company NewsAccording to the announcement of the National Healthcare Security Administration of China on Novembe
In March 2024, Kolupin? (Tunlametinib) was approved in China for use in patients with advanced NRAS-
The first worldwide MEK inhibitor approved for treating advanced NRAS-mutant melanoma.The first MEK
On January 23, 2024, Shanghai Kechow Pharma Inc. (“KeChow Pharma”) and Sinopharm Global Procurement
During the European Society for Medical Oncology (ESMO) meeting held from October 20 to 24, 2023, in
On September 27, 2023, Tianjin Municipal Bureau of Science and Technology arranged for a panel of ex
